Safety and efficacy of ibrutinib in a patient with severe renal impairment

Safety and efficacy of ibrutinib in a patient with severe renal impairment

Not available

Bibliographic Details
Main Authors:	Kalman Filanovsky, Lev Shvidel
Format:	Article
Language:	English
Published:	MDPI AG 2017-09-01
Series:	Hematology Reports
Subjects:	Lymphoma, Ibrutinib, chronic renal failure
Online Access:	http://www.pagepress.org/journals/index.php/hr/article/view/7078

Similar Items

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
by: Michael Wang, et al.
Published: (2017-11-01)

Synergistic Inhibition of Burkitt’s Lymphoma with Combined Ibrutinib and Lapatinib Treatment
by: Chae-Eun YANG, et al.
Published: (2023-12-01)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
by: Walter Hanel, et al.
Published: (2023-02-01)

Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience
by: Alessandro Broccoli, et al.
Published: (2021-12-01)

Ibrutinib: A narrative drug review
by: Pritesh Naresh Munot, et al.
Published: (2020-01-01)

Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
by: Anna Mair, et al.
Published: (2021-09-01)

Hodgkin's variant of Richter transformation during ibrutinib therapy: A case report and review of the literature
by: Carolina Afonso, et al.
Published: (2022-10-01)

Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia
by: Ayşe Kaya, et al.
Published: (2024-03-01)

Severe Lymphocytosis in a Case of Diffuse Large B-Cell Lymphoma Treated by Ibrutinib
by: Semra Paydaş, et al.
Published: (2021-12-01)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
by: Denlinger NM, et al.
Published: (2018-03-01)

Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report
by: Danuta Krasowska, et al.
Published: (2020-09-01)

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL
by: Caroline Dartigeas, et al.
Published: (2022-09-01)

Ibrutinib-induced cardiomyopathy
by: Htay Htay Kyi, et al.
Published: (2019-01-01)

İbrutinib Sonrası Gelişen Dev Ekimoz ve Hematom: Olgu Sunumu
by: Aynur Uğur Bilgin, et al.
Published: (2017-03-01)

Ibrutinib response in a patient with refractory mixed essential cryoglobulinemia
by: Haya Jamali, et al.
Published: (2023-05-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Isacco Ferrarini, et al.
Published: (2022-04-01)

Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis
by: Liwei Lv, et al.
Published: (2021-07-01)

EXPERIENCE WITH IBRUTINIB IN PATIENTS WITH REFRACTORY AND RECURRENT B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
by: T. V. SOROKINA, et al.
Published: (2017-06-01)

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant
by: Samip Master, et al.
Published: (2017-06-01)

Multifocal periungual granulation tissue related to ibrutinib therapy
by: Aatman Shah, MD, et al.
Published: (2020-02-01)

Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
by: Narendranath Epperla, et al.
Published: (2022-07-01)

Ibrutinib-associated atrial fibrillation treatment with catheter ablation
by: Ridhima Kapoor, MD, et al.
Published: (2021-11-01)

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
by: Francesca Romana Mauro, et al.
Published: (2021-06-01)

Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
by: Nurhilal Büyükkurt, et al.
Published: (2023-06-01)

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
by: Yuchen Zhang, et al.
Published: (2022-11-01)

Ibrutinib associated cardiovascular events in a patient wearing an implanted loop recorder
by: Daniel Rivera, et al.
Published: (2021-06-01)

Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre‐ibrutinib era: Incidence and risk factors
by: Peter Georgantopoulos, et al.
Published: (2019-05-01)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
by: Ujjani C, et al.
Published: (2020-08-01)

Ibrutinib-Induced Skin Rash
by: Sudhir Kirar, et al.
Published: (2021-02-01)

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Research in context
by: Urban Novak, et al.
Published: (2023-10-01)

Ibrutinib dose modifications in the management of CLL
by: Camille Hardy-Abeloos, et al.
Published: (2020-06-01)

Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia
by: Gülşen İskender, et al.
Published: (2020-08-01)

Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
by: Anıl Tombak, et al.
Published: (2021-12-01)

Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma
by: Fouad Choueiry, et al.
Published: (2021-04-01)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
by: Young‐Woo Jeon, et al.
Published: (2019-11-01)

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
by: Gianluigi Reda, et al.
Published: (2018-06-01)

Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice
by: Vladimir I. Vorobyev, et al.
Published: (2021-07-01)

Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation
by: Francesca Maria Quaglia, et al.
Published: (2019-08-01)

Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia
by: Josh A. Hammel, MD, et al.
Published: (2017-05-01)

Ibrutinib impairs IGF-1-dependent activation of intracellular Ca handling in isolated mouse ventricular myocytes
by: Daniel Tarnowski, et al.
Published: (2023-08-01)